A promising approach of GD2-specific chimeric antigen receptor (CAR) T cells with CD28/4.1BB costimulatory domains for treatment of GD2+sarcomas

被引：0

作者：

De Angelis, B. ^{[1
]}

Camera, A. ^{[1
]}

Orlando, D. ^{[1
]}

Guercio, M. ^{[1
]}

Sinibaldi, M. ^{[1
]}

Cembrola, B. M. ^{[1
]}

Caruso, S. ^{[1
]}

Abbaszadeh, Z. ^{[1
]}

Bovetti, K. ^{[1
]}

Milano, G. M. ^{[1
]}

Russo, I. ^{[1
]}

De Vito, R. ^{[1
]}

Quintarelli, C. ^{[1
]}

Locatelli, F. ^{[1
]}

机构：

[1] Osped Pediat Bambino Gesu, Rome, Italy

来源：

HUMAN GENE THERAPY | 2019年 / 30卷 / 11期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

P170

引用

页码：A69 / A70

页数：2

共 44 条

[31] CD2, the First Identified T cell Co-Stimulator, Demonstrates More Effective Chimeric Antigen Receptor Activity Over CD28 and 4-1BB
Posey, Avery D., Jr.
June, Carl H.
MOLECULAR THERAPY, 2015, 23 : S83 - S83
[32] Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma
Till, Brian G.
Jensen, Michael C.
Qian, Xiaojun
Wang, Jinjuan
Gopal, Ajay K.
Maloney, David G.
Lindgren, Catherine G.
Lin, Yukang
Pagel, John M.
Budde, Lihua E.
Raubitschek, Andrew
Forman, Stephen
Greenberg, Philip
Riddell, Stanley R.
Press, Oliver W.
BLOOD, 2010, 116 (21) : 248 - 249
[33] Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
Gargett, Tessa
Brown, Michael P.
CYTOTHERAPY, 2015, 17 (04) : 487 - 495
[34] Tumor-Associated Macrophages Via Up-Regulation of PD1 Ligands Protect Neuroblastoma from Immunotherapy With NKT Cells Expressing GD2-Specific Chimeric Antigen Receptor
Liu, Daofeng
Courtney, Amy N.
Heczey, Andras
Marinova, Ekaterina
Tian, Gengwen
Guo, Linjie
Gao, Xiuhua
Dotti, Gianpietro
Metelitsa, Leonid S.
MOLECULAR THERAPY, 2015, 23 : S205 - S205
[35] Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics
Zhong, Qi
Zhu, Yang-min
Zheng, Li-ling
Shen, Hui-juan
Ou, Rui-ming
Liu, Zhi
She, Yan-ling
Chen, Rui
Li, Cheng
Huang, Jing
Yao, Meng-dong
Zhang, Qing
Liu, Shuang
ACTA HAEMATOLOGICA, 2018, 140 (03) : 131 - 140
[36] CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28
Haso, Waleed
Qin, Haiying
Zhang, Ling
Orentas, Rimas J.
Fry, Terry J.
BLOOD, 2013, 122 (21)
[37] GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Gargett, Tessa
Yu, Wenbo
Dotti, Gianpietro
Yvon, Eric S.
Christo, Susan N.
Hayball, John D.
Lewis, Ian D.
Brenner, Malcolm K.
Brown, Michael P.
MOLECULAR THERAPY, 2016, 24 (06) : 1135 - 1149
[38] OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Hombach, Andreas A.
Heiders, Johannes
Foppe, Marcel
Chmielewski, Markus
Abken, Hinrich
ONCOIMMUNOLOGY, 2012, 1 (04):
[39] Anti-GD2-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy/prostate-specific-membrane-antigen-CAR-T-cell-therapy-Shanghai-Bioray-Laboratory-IncCytokine release syndrome
Reactions Weekly, 2024, 2002 (1) : 46 - 46
[40] 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
Dai, Qiang
Han, Ping
Qi, Xinyue
Li, Fanlin
Li, Min
Fan, Lilv
Zhang, Huihui
Zhang, Xiaoqing
Yang, Xuanming
FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →